THE NEXT
CHEMISTRY TARGET.

The patent’s chlodantane formulation group ran 56.23 minutes versus 27.69 minutes in controls at 40°C. These are mouse results for a specific formulation, not a general claim for all chlodantane preparations.

The reported running-time mean was 35.0% above Bemitil’s in the same patent experiment. The formulation and Bemitil were administered at different doses. This comparison does not establish clinical superiority or equivalent dosing.

Confirm identity, characterize formulation and measure exposure before testing the performance signal. Related ADK candidates supply further design hypotheses.

RU2704126C2 belongs to a third party. Compound selection, formulation strategy and commercialization require patent-family and freedom-to-operate analysis. Antaeus does not claim ownership of that filing.